Two-year outcomes following PSMA PET and MRI guided prostate SABR with simultaneous focal boost: a brief report from the ARGOS-CLIMBER phase 1/2 trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 42744076.
- Also identified by DOI 10.1016/j.radonc.2026.111786.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
ARGOS-CLIMBER is a phase 1/2 trial evaluating PSMA PET and MRI guided prostate SABR with a simultaneous boost to intraprostatic and nodal disease in men with unfavourable intermediate and high-risk prostate cancer. The updated results demonstrate acceptable safety and quality of life with high biochemical and imaging response rates.